Our Technology
CyPep-1 selectively targets and disrupts cancer cell membranes. This releases tumor neoantigens to the immune system, allowing it to mount a systemic, cancer-specific, immune response. Moreover, CyPep-1 inhibits the beta-catenin pathway, disrupting tumor growth and further stimulating the immune system.